IdeS

Immunoglobulin-degrading enzyme of Streptococcus pyogenes · Hansa Biopharma AB

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for IdeS, covering 2016-05-23 to 2022-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease [Phase 2]